Ablevia

biotech

Pfeil nach unten 2.png
 
 

 Ablevia removes disease-causing and other undesired antibodies 

 [(c) stock.adobe.com]

Pfeil nach unten 2.png
 
Ablevia biotech GmbH
Maria Jacobi Gasse 1, MQM 3.2
1030 Vienna
AUSTRIA
contact us

member of

VBC_LOGO_WHITE_only writing.png
VBC logo white transparent.png
funding
& partners
AWS_logo_Schrift links_3Zeilig_final.jpg
ffg_logo_en_2018_rgb_300.png

supported by BMWFW / aws & FFG

Initial private investments in combination with non-dilutive funding by federal institutions, supports technology setup and facilitates Ablevia's independence in seed phase. Ablevia has received funding from the Austrian Research Promotion Agency (FFG Early Stage program) and was awarded a Seedfinancing program by the Austrian promotional bank aws.

Austrian Research Promotion Agency

Location on Google Maps - here

Pfeil nach unten 2.png

(c) 2019 Ablevia biotech GmbH, Vienna Biocenter, Österreich

selective antibody removal therapeutics